Form 8-K - Current report:
SEC Accession No. 0001104659-25-056679
Filing Date
2025-06-05
Accepted
2025-06-05 08:00:19
Documents
13
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517193d1_8k.htm   iXBRL 8-K 28740
2 EXHIBIT 10.1 tm2517193d1_ex10-1.htm EX-10.1 41646
  Complete submission text file 0001104659-25-056679.txt   245805

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eyen-20250530.xsd EX-101.SCH 3014
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20250530_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20250530_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2517193d1_8k_htm.xml XML 3685
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 251025047
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)